Aidoc Raises $150 Million Series E Led by Goldman Sachs for Clinical AI Model

Aidoc, a developer of artificial intelligence software for medical imaging, has raised $150 million in a Series E funding round led by Growth Equity at Goldman Sachs Alternatives, the company and its lead investor announced on April 29. General Catalyst, SoftBank Vision Fund 2 and NVentures, NVIDIA's venture capital arm, also took part.

The round brings Aidoc's total funding to more than $500 million, less than a year after a growth round led by General Catalyst and Square Peg, according to the release. The latest round came nine months after Aidoc disclosed another $150 million financing, MedTech Dive reported.

From single algorithms to a foundation model

Aidoc built its own clinical foundation model, called CARE, and deploys it through an enterprise platform called aiOS. In January, the Food and Drug Administration cleared a multi-triage technology designed to detect 11 conditions, including appendicitis and liver injury, in CT images of the chest, abdomen and pelvis, MedTech Dive reported. Aidoc had received 510(k) clearance in 2024 for an algorithm that analyzes CT scans of the cervical spine, according to the publication.

The company said its software is deployed in nearly 2,000 hospitals and analyzes more than 60 million patient cases a year. Globes, an Israeli business news site, described Aidoc as an Israeli clinical AI company.

"By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error," co-founder and CEO Elad Walach said in the release. "This funding accelerates comprehensive disease coverage and advances end-to-end AI across CT and X-ray, spanning the full workflow including pixel to draft report within two years."

Where the money goes

Aidoc said the capital will fund further development of CARE, expansion into additional clinical indications and new capabilities such as automated draft creation of imaging reports. It will also pay for wider global deployment of aiOS, which the company said is designed to let hospitals manage and govern multiple AI tools from one platform.

"Aidoc pairs advanced technology with regulatory rigor in a way that few companies have achieved," said Christian Resch, a partner in Growth Equity at Goldman Sachs Alternatives. He said health systems describe results including improved radiology efficiency, shorter lengths of stay and measurable financial returns; those are the investor's characterizations.

Aidoc said hospitals are moving away from standalone AI tools toward systems deployed across entire health networks, and that foundation models make it possible to cover many conditions and imaging types from a single architecture. The release did not say when Aidoc expects to seek FDA clearance for the draft-report features.